Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-13
2010-12-21
Tucker, Zachary (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S349000
Reexamination Certificate
active
07855208
ABSTRACT:
This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
REFERENCES:
patent: 3293251 (1966-12-01), Cignarolla et al.
patent: 2003/0225268 (2003-12-01), Bunnelle et al.
patent: 2005/0137226 (2005-06-01), Ji et al.
patent: 2005/0250808 (2005-11-01), Xie et al.
patent: WO-98/54182 (1998-12-01), None
patent: WO-00/44755 (2000-08-01), None
patent: WO-2004/016616 (2004-02-01), None
patent: WO-2004/016617 (2004-02-01), None
patent: WO-2004/022556 (2004-03-01), None
patent: WO-2004/043960 (2004-05-01), None
patent: WO-2006/005608 (2006-01-01), None
patent: WO-2006/040352 (2006-04-01), None
patent: WO-2006/04571 (2006-05-01), None
patent: WO-2006/045716 (2006-05-01), None
patent: WO-2006/058879 (2006-06-01), None
patent: WO-2006/087306 (2006-08-01), None
patent: WO-2007/065892 (2007-06-01), None
Liu and Zhao, “Nicotine attenuates β-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures” British Journal of Pharmacology, vol. 141, pp. 746-754 (2004).
Giunta et al, “Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV gp120” Brain Research Bulletin, vol. 64, pp. 165-170 (2004).
Suto and Zacharias, “Neuronal nicotinic acetylcholine receptors as drug targets” Expert Opinion on Therapeutic Targets, vol. 8(2), pp. 61-64 (2004).
Tariq et al, “Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats” Brain Research Bulletin, vol. 67, pp. 161-168 (2005).
Hernandez and Terry, Jr., “Repeated Nicotine Exposure in Rats: Effects on Memory Function, Cholinergic Markers and Nerve Growth Factor” Neuroscience, vol. 130, pp. 997-1012 (2006).
Gotti et al, “Brain Neuronal Nicotinic Receptors as New Targets for Drug Discovery” Current Pharmaceutical Design, vol. 12, pp. 407-428 (2006).
Nielsen Elsebet Ostergaard
Olsen Gunnar M.
Peters Dan
Timmermann Daniel B.
Birch & Stewart Kolasch & Birch, LLP
NeuroSearch A/S
Tucker Zachary
LandOfFree
3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3, 9-diazabicyclo(3.3.1)non-3-yl-aryl methanone derivatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4234044